Sacubitril valsartan patent expiry?

Sacubitril/valsartan (Entresto) patent expiry depends on the country, because different patents expire at different times (often with multiple patents for composition, formulations, and methods of use).

Quick high-level answer (global)

• In the US, key patent protection for sacubitril/valsartan is generally expected to run into the 2020s, with earlier exclusivity around 2022–2024 for some aspects, and later/remaining patents potentially extending protection into the mid/late 2020s (depending on what’s being measured: “patent expiry” vs. “exclusivity” vs. regulatory exclusivity).
• In the EU/UK, expiry schedules differ by jurisdiction and by which patent(s) are being considered; similar extensions can push some exclusivity into the mid/late 2020s.

The important nuance

There isn’t a single universal “patent expiry date”:

• Brand protection can include multiple patents, plus regulatory data/market exclusivity.
• Different generic/biosimilar entry dates depend on what barriers are still in force and whether ANDA filings can “design around” specific patents.

If you tell me your location, I can be precise

Which country/region do you mean?

• US
• UK
• EU (which country?)
• Canada
• India
• Another country

Also, do you want the earliest possible generic entry date, or the specific last patent expiry date for sacubitril/valsartan?